Pretzel Therapeutics Presents PX578 Data Supporting POLG Disease Treatment

Why It Matters

PX578 targets the only approved‑free therapeutic pathway for POLG disease, offering a potential disease‑modifying option for a condition with no current treatments.

Key Takeaways

• PX578 activates POLG, boosting mitochondrial DNA.
• Preclinical models show improved respiration and survival.
• Effective across four common POLG mutations (≈70% patients).
• Phase 1 completed early 2026; Phase 2 slated later 2026.
• First small‑molecule approach for mitochondrial DNA depletion syndromes.

Pulse Analysis

Mitochondrial DNA depletion syndromes (MDDS) represent a cluster of rare, often fatal disorders caused by defects in the enzymes that replicate mitochondrial DNA. Among them, POLG disease stands out for its severe neurological, muscular, and metabolic manifestations, and it remains without an approved disease‑modifying therapy. The unmet clinical need has driven biotech firms to explore strategies that directly address the root cause—insufficient mitochondrial DNA—rather than merely managing symptoms. This backdrop underscores the strategic importance of Pretzel Therapeutics' focus on POLG activation.

PX578 is a first‑in‑class, orally bioavailable small molecule that binds to and stimulates the activity of POLG, the enzyme responsible for replicating mitochondrial DNA. Preclinical studies reported across multiple cell lines and animal models showed that PX578 consistently raised mtDNA copy number, enhanced oxidative phosphorylation, and normalized liver function biomarkers. Notably, the compound retained activity against the four most prevalent POLG mutations, which together account for roughly 70% of the patient population, suggesting broad applicability within the heterogeneous genetic landscape of MDDS. These data provide a mechanistic proof‑of‑concept that pharmacologic activation of POLG can reverse the energy deficit at the cellular level.

The therapeutic pipeline is now transitioning from safety assessment to efficacy evaluation. A Phase 1 trial involving healthy volunteers began in 2025 and is expected to conclude in the first half of 2026, establishing tolerability and pharmacokinetics. Assuming favorable outcomes, Pretzel plans to launch a Phase 2 study in POLG patients later that year, positioning PX578 as a potential first disease‑modifying agent for this orphan indication. Success could catalyze a new class of mitochondrial therapeutics, attract significant investment, and reshape treatment paradigms for a spectrum of rare metabolic disorders.